Structure Therapeutics (GPCR) News Today $34.72 +1.37 (+4.11%) (As of 06:15 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Pier Capital LLC Grows Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR)Pier Capital LLC raised its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 32.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 134,291 shares of the company's stock after acquDecember 8 at 6:58 AM | marketbeat.comWellington Management Group LLP Purchases 221,851 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)Wellington Management Group LLP lifted its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 2.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 7,769,771 shares of the company's stock after purchasing an additional 221,851 shares dDecember 8 at 5:21 AM | marketbeat.comEquities Analysts Offer Predictions for GPCR FY2025 EarningsDecember 7 at 2:29 AM | americanbankingnews.comOptimistic Outlook on Structure Therapeutics: Promising Drug Development Progress and Future MilestonesDecember 6 at 4:54 PM | markets.businessinsider.comStructure Therapeutics (NASDAQ:GPCR) Shares Gap Up - What's Next?Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Still a Buy?December 6 at 12:00 PM | marketbeat.comFY2024 Earnings Estimate for GPCR Issued By HC WainwrightStructure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Structure Therapeutics in a research report issued to clients and investors on Wednesday, December 4th. HC Wainwright analyst A. Ghosh expects that the company will pDecember 6 at 8:02 AM | marketbeat.comLeerink Partnrs Issues Pessimistic Outlook for GPCR EarningsStructure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Leerink Partnrs decreased their FY2024 earnings per share estimates for Structure Therapeutics in a report released on Tuesday, December 3rd. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings per share oDecember 6 at 8:02 AM | marketbeat.comStructure Therapeutics Inc. (NASDAQ:GPCR) Holdings Boosted by Bank of Montreal CanBank of Montreal Can grew its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 71.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,502 shares of the company's stock after pDecember 6 at 3:19 AM | marketbeat.comStructure Therapeutics price target raised to $91 from $86 at JMP SecuritiesDecember 5, 2024 | markets.businessinsider.comReadystate Asset Management LP Purchases New Position in Structure Therapeutics Inc. (NASDAQ:GPCR)Readystate Asset Management LP purchased a new stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 84,000 shares of the company's sDecember 5, 2024 | marketbeat.comPoint72 Asset Management L.P. Raises Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)Point72 Asset Management L.P. lifted its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 196.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,238,268 shares of the company's stock after buying an additionalDecember 5, 2024 | marketbeat.comHC Wainwright & Co. Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Buy RecommendationDecember 4, 2024 | msn.comJanus Henderson Group PLC Has $173.62 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)Janus Henderson Group PLC grew its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 18.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,956,878 shares of the company's stock after purchasiDecember 4, 2024 | marketbeat.comStructure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by Cinctive Capital Management LPCinctive Capital Management LP grew its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 111.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 32,094 shares of the company's stock after purchasing an additional 16,December 4, 2024 | marketbeat.comStructure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Up 7.6% in NovemberStructure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) was the target of a significant growth in short interest in November. As of November 15th, there was short interest totalling 11,230,000 shares, a growth of 7.6% from the October 31st total of 10,440,000 shares. Based on an average daily trading volume, of 733,600 shares, the days-to-cover ratio is presently 15.3 days. Currently, 20.7% of the company's stock are sold short.December 3, 2024 | marketbeat.comBaker BROS. Advisors LP Invests $3.75 Million in Structure Therapeutics Inc. (NASDAQ:GPCR)Baker BROS. Advisors LP bought a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 85,500 shares of the company's stock, valued aDecember 2, 2024 | marketbeat.comStructure Therapeutics Inc. (NASDAQ:GPCR) Holdings Lifted by Fmr LLCFmr LLC grew its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 6.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,128,444 shares of the company's stock after buyiDecember 2, 2024 | marketbeat.comBellevue Group AG Acquires 72,437 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)Bellevue Group AG boosted its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 13.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 629,758 shares of thDecember 1, 2024 | marketbeat.comFred Alger Management LLC Decreases Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)Fred Alger Management LLC cut its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 76.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,713 shares of the company's stock after selling 220,9December 1, 2024 | marketbeat.comStructure Therapeutics Inc. (NASDAQ:GPCR) is Vestal Point Capital LP's 6th Largest PositionVestal Point Capital LP increased its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 105.4% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,150,000 shares of the company's stock after purchasing an additional 590,000 shares duringNovember 29, 2024 | marketbeat.comStructure Therapeutics Inc. (GPCR): Among the NASDAQ Stocks with Biggest Upside Potential According to AnalystsNovember 22, 2024 | msn.comStructure Therapeutics (NASDAQ:GPCR) Trading Up 9.3% - Time to Buy?Structure Therapeutics (NASDAQ:GPCR) Trading 9.3% Higher - Here's What HappenedNovember 22, 2024 | marketbeat.comStructure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Rating of "Buy" from AnalystsStructure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) has received an average recommendation of "Buy" from the six brokerages that are covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price targetNovember 20, 2024 | marketbeat.comSepterna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 MilestonesNovember 19, 2024 | benzinga.comFY2024 Earnings Forecast for GPCR Issued By Lifesci CapitalStructure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Stock analysts at Lifesci Capital raised their FY2024 earnings estimates for shares of Structure Therapeutics in a research note issued to investors on Wednesday, November 13th. Lifesci Capital analyst M. Belghiti now expects that the compNovember 18, 2024 | marketbeat.comMorgan Stanley Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)November 15, 2024 | markets.businessinsider.comStructure Therapeutics (NASDAQ:GPCR) Trading Down 8.9% - Here's What HappenedStructure Therapeutics (NASDAQ:GPCR) Trading Down 8.9% - Time to Sell?November 15, 2024 | marketbeat.comStructure Therapeutics to Participate in the Jefferies London Healthcare ConferenceNovember 15, 2024 | globenewswire.comRA Capital Management, L.P. Expands Stake in Structure Therapeutics Inc.November 15, 2024 | gurufocus.comStructure Therapeutics, Inc.: Promising Advances in Metabolic Treatments Drive Buy RecommendationNovember 15, 2024 | markets.businessinsider.comGSA Capital Partners LLP Makes New $1.34 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)GSA Capital Partners LLP acquired a new stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 30,464 shares of the company's stock, valuNovember 14, 2024 | marketbeat.comStructure Therapeutics expects cash to fund operations through at least 2027November 14, 2024 | markets.businessinsider.comStructure Therapeutics doses first patients in ACCESS clinical studyNovember 14, 2024 | markets.businessinsider.comStructure Therapeutics Reports Third Quarter 2024 Financial Results and Recent HighlightsNovember 13, 2024 | markets.businessinsider.comStructure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for ObesityNovember 13, 2024 | globenewswire.comabrdn plc Has $9.53 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)abrdn plc grew its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 132.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 217,083 shares of the company's stock after buying an additional 123,7November 3, 2024 | marketbeat.comStructure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024October 31, 2024 | markets.businessinsider.comStructure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Recommendation of "Buy" by AnalystsStructure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) has been given a consensus recommendation of "Buy" by the six analysts that are presently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price targetOctober 26, 2024 | marketbeat.comStructure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity PatientsOctober 22, 2024 | seekingalpha.comCan Roche Challenge Lilly and Novo in the Weight Loss Market? (GPCR)One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.October 22, 2024 | marketbeat.comEvan Seigerman’s Buy Rating Highlights Structure Therapeutics’ Innovative Approach in Obesity Treatment MarketOctober 22, 2024 | markets.businessinsider.comConsumer, labor groups urge FTC to block Catalent sale to Novo Holdings - reportOctober 17, 2024 | seekingalpha.comGriffin Asset Management Inc. Takes $634,000 Position in Structure Therapeutics Inc. (NASDAQ:GPCR)Griffin Asset Management Inc. bought a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 14,450 shares of the company's stock, valuedOctober 17, 2024 | marketbeat.comStructure Therapeutics (GPCR): Innovating Oral Therapies for Obesity and DiabetesOctober 16, 2024 | msn.comExchange Traded Concepts LLC Grows Stake in Structure Therapeutics Inc. (NASDAQ:GPCR)Exchange Traded Concepts LLC raised its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 191.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,101 shares of the company's stock after purchaOctober 16, 2024 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Shares Down 2.7% - Here's What HappenedStructure Therapeutics (NASDAQ:GPCR) Stock Price Down 2.7% - Time to Sell?October 11, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Purchases 32,839 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)The Manufacturers Life Insurance Company grew its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 53.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 94,370 shares of the cOctober 8, 2024 | marketbeat.comBank of Montreal Can Makes New Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)Bank of Montreal Can bought a new stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 27,094 shares of the company's stock, valued at approximatelyOctober 7, 2024 | marketbeat.com35,700 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Bought by Renaissance Technologies LLCRenaissance Technologies LLC bought a new position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 35,700 shares of the company's stock, valued at approOctober 5, 2024 | marketbeat.comMarshall Wace LLP Purchases 40,693 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)Marshall Wace LLP lifted its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 115.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 75,934 shares of the company's stock after aOctober 4, 2024 | marketbeat.com Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address No one’s talking about these Trump trades (Ad)As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.” Go here to see how you can start accessing these opportunities today GPCR Media Mentions By Week GPCR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GPCR News Sentiment▼0.730.68▲Average Medical News Sentiment GPCR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GPCR Articles This Week▼264▲GPCR Articles Average Week Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Jazz Pharmaceuticals News Madrigal Pharmaceuticals News Nuvalent News Elanco Animal Health News Blueprint Medicines News Corcept Therapeutics News Cytokinetics News Viking Therapeutics News Ionis Pharmaceuticals News TG Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GPCR) was last updated on 12/9/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
